Poly Medicure vs Windlas Biotech vs Shilpa Medicare: Which Stock Should You Track
- September 24, 2026
- Posted by: Kunal Singla
- Category: Market
Poly Medicure PE 55.94, mkt cap Rs 17,504 crore. Windlas Biotech PE 33.46, mkt cap Rs 2,223 crore. Shilpa Medicare PE 68.23, mkt cap Rs 20,284 crore.
Quick Answer
Poly Medicure vs Windlas Biotech vs Shilpa Medicare is a side-by-side comparison of three companies from the Medical Devices space. On this comparison, Poly Medicure carries a market capitalisation of about Rs 17,504 crore against Rs 2,223 crore for Windlas Biotech and Rs 20,284 crore for Shilpa Medicare, with return on equity of 10.37%, 11.44% and 9.39% respectively. Each company’s numbers are presented here without a declared better pick, since the right stock depends on an investor’s own criteria.
Poly Medicure vs Windlas Biotech vs Shilpa Medicare starts with the core numbers most investors compare within the Medical Devices segment: market capitalisation, valuation multiples, profitability and dividend yield. Figures below are sourced as of September 2026 and will shift with daily price moves.
All three names sit in the Medical Devices bucket, which makes them a natural set to place side by side rather than a random trio of unrelated businesses.
Click Here – Get Free Investment Predictions
Poly Medicure, Windlas Biotech and Shilpa Medicare: Company Overview
Poly Medicure is a listed Indian company in the Medical Devices space, tracked here on book value, return ratios and valuation alongside its peers in this comparison.
Windlas Biotech is a listed Indian company in the Medical Devices space, tracked here on book value, return ratios and valuation alongside its peers in this comparison.
Shilpa Medicare is a listed Indian company in the Medical Devices space, tracked here on book value, return ratios and valuation alongside its peers in this comparison.
Poly Medicure vs Windlas Biotech vs Shilpa Medicare: Valuation and Profitability Snapshot
| Metric | Poly Medicure | Windlas Biotech | Shilpa Medicare |
|---|---|---|---|
| Market Cap (approx.) | Rs 17,504 crore | Rs 2,223 crore | Rs 20,284 crore |
| PE Ratio (TTM) | 55.94 | 33.46 | 68.23 |
| PB Ratio | 5.64 | 3.83 | 7.83 |
| Return on Equity (ROE) | 10.37% | 11.44% | 9.39% |
| EPS (TTM, Rs) | 30.87 | 32.20 | 15.20 |
| Dividend Yield | 0.20% | 0.58% | 0.06% |
| Debt to Equity | 0.11 | 0.06 | 0.25 |
| Book Value per Share (Rs) | 306.45 | 281.35 | 132.49 |
Check the Univest Screener for Live Data
On valuation, Poly Medicure trades at a PE of 55.94 and a PB of 5.64, Windlas Biotech at a PE of 33.46 and a PB of 3.83, while Shilpa Medicare trades at a PE of 68.23 and a PB of 7.83. On return on equity, the three post 10.37%, 11.44% and 9.39% respectively, and on dividend yield they stand at 0.20%, 0.58% and 0.06%.
Poly Medicure vs Windlas Biotech vs Shilpa Medicare: Latest Quarterly Results
| Company | Latest Quarter Revenue | Latest Quarter Net Profit | YoY Change (Revenue) | QoQ Change (Revenue) |
|---|---|---|---|---|
| Poly Medicure | Rs 558.79 crore | Rs 85.27 crore | +25.5% | +1.2% |
| Windlas Biotech | Rs 242.85 crore | Rs 15.99 crore | +17.0% | +2.2% |
| Shilpa Medicare | Rs 468.91 crore | Rs 100.88 crore | +43.0% | +6.9% |
Quarterly figures above are the most recent reported quarter for each company (Q1 FY28, quarter ended June 2026), compared with the year-ago and preceding quarter.
Download the Univest iOS App or Univest Android App to track Poly Medicure, Windlas Biotech and Shilpa Medicare live prices.
What Should Investors Look at Beyond These Numbers?
Beyond the metrics above, investors comparing these three medical devices names should track quarter-on-quarter revenue and margin trends, management commentary on demand and cost drivers, and any sector-specific regulatory developments, since a single-quarter snapshot can shift quickly.
Conclusion
Poly Medicure vs Windlas Biotech vs Shilpa Medicare highlights how differently three companies in the same medical devices segment can score across valuation, profitability and dividend metrics, even when operating in a similar space. This comparison does not declare a winner; investors should weigh these figures against their own research and risk appetite. Please read the disclaimer below before making any investment decision.
Disclaimer: Data and figures in this article are sourced from publicly available information as of September 2026 and may not reflect real-time prices. Please verify all data independently before making any investment decision. This comparison does not recommend or endorse any single stock over another; investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
FAQs on Poly Medicure vs Windlas Biotech vs Shilpa Medicare
What is the market cap difference between Poly Medicure, Windlas Biotech and Shilpa Medicare?
Ans. As of September 2026, Poly Medicure has a market cap of approximately Rs 17,504 crore, Windlas Biotech is at approximately Rs 2,223 crore, and Shilpa Medicare is at approximately Rs 20,284 crore.
Which of the three has the highest PE ratio?
Ans. Among Poly Medicure, Windlas Biotech and Shilpa Medicare, the PE ratios stand at 55.94, 33.46 and 68.23 respectively as of September 2026.
Which of the three has the highest ROE?
Ans. Poly Medicure, Windlas Biotech and Shilpa Medicare post ROE of 10.37%, 11.44% and 9.39% respectively as of September 2026.
Which of these three stocks pays the highest dividend yield?
Ans. Poly Medicure, Windlas Biotech and Shilpa Medicare carry dividend yields of 0.20%, 0.58% and 0.06% respectively.
What is the debt to equity ratio for Poly Medicure, Windlas Biotech and Shilpa Medicare?
Ans. Poly Medicure carries a debt to equity of 0.11, Windlas Biotech of 0.06, and Shilpa Medicare of 0.25.
Which of the three trades at the highest price to book value?
Ans. Poly Medicure, Windlas Biotech and Shilpa Medicare trade at price to book ratios of 5.64, 3.83 and 7.83 respectively.
Is one of Poly Medicure, Windlas Biotech or Shilpa Medicare better than the others?
Ans. This comparison does not declare one stock better than another; each company scores differently across valuation, profitability and dividend metrics, and the right fit depends on an individual investor’s own criteria and research.
